Global Thrombocytopenia Market, By Type (Idiopathic Thrombocytopenic, Thrombotic Thrombocytopenic, Drug-induced Thrombocytopenia), Drugs (Danazol, Intravenous Immune Globulin, Rituximab, Eltrombopag, Romiplostim, Splenectomy, Corticosteroid, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Market Analysis and Size
In recent years, the thrombocytopenia market is anticipated to grow rapidly during the forecast period. A patient with thrombocytopenia has a low number of platelets in their blood. Inefficient platelet generation, platelet splenic sequestration, and platelet degradation that occurs too quickly are the main causes of thrombocytopenia. According to a study published in Professional Med J in 2014 titled Frequency of Thrombocytopenia, the frequency of thrombocytopenia is higher in persons aged 60 and older who have non-cirrhotic liver disease.
Data Bridge Market Research analyses that the thrombocytopenia market was valued at USD 4.14 billion in 2021 and is expected to reach USD 6.02 billion by 2029, registering a CAGR of 4.79% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Thrombocytopenia is a condition in which the number of platelets in your blood is abnormally low. Platelets are blood cells that are generated from bigger cells in the bone marrow. Platelets bind together to create a plug to seal the wound. A blood clot is the name for this blockage. Because a blood clot is also known as a thrombus, platelets are also known as thrombocytes.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Idiopathic Thrombocytopenic, Thrombotic Thrombocytopenic, Drug-induced Thrombocytopenia), Drugs (Danazol, Intravenous Immune Globulin, Rituximab, Eltrombopag, Romiplostim, Splenectomy, Corticosteroid, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), Amneal Pharmaceuticals LLC. (US), Amgen Inc. (US), Boehringer Ingelheim International GmbH. (Germany), Eisai Co., Ltd. (Japan)
|
|
Market Opportunities
|
|
Thrombocytopenia Market Dynamics
Drivers
- Increasing prevalence of autoimmune diseases
The rising prevalence of autoimmune diseases is a primary driver of the thrombocytopenia market's growth. Along with this, the increasing incidences of pathological conditions and bleeding disorders will influence the market dynamics during the forecast period.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of thrombocytopenia market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the thrombocytopenia market. Additionally, high disposable income and increase in the prevalence rate of thrombocytopenia across the globe will result in the expansion of the market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the thrombocytopenia market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the thrombocytopenia market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment of thrombocytopenia will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the thrombocytopenia market. Additionally, side effects linked with the treatment and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This thrombocytopenia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the thrombocytopenia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
People of various ages, races, and genders can develop thrombocytopenia. Approximately 5% of pregnant women develop moderate thrombocytopenia shortly before giving birth for unknown causes.
Thrombocytopenia market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Thrombocytopenia Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of thrombocytopenia in recent months.
Recent Development
- In November 2020, The U.S. Food and Drug Administration (FDA) had granted Fast Track Designation (FTD) to rilzabrutinib. It is the oral investigational Bruton’s tyrosine kinase (BTK) inhibitor that is used for the treatment of immune thrombocytopenia (ITP). The capacity of Rilzabrutinib to block inflammatory immune cells, abolish autoantibody damaging signalling, and prevent new autoantibody formation without depleting B cells has been demonstrated in studies.
Global Thrombocytopenia Market Scope
The thrombocytopenia market is segmented on the basis of type, drugs, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Idiopathic Thrombocytopenic
- Thrombotic Thrombocytopenic
- Drug-induced Thrombocytopenia
On the basis of type, the market is segmented into idiopathic thrombocytopenic, thrombotic thrombocytopenic and drug-induced thrombocytopenia.
Drugs
- Danazol
- Intravenous Immune Globulin
- Rituximab
- Eltrombopag
- Romiplostim
- Splenectomy
- Corticosteroid
- Others
Based on drugs, the market is segmented into danazol, intravenous immune globulin, rituximab, eltrombopag, romiplostim, splenectomy, corticosteroids and others
Route of Administration
- Oral
- Parenteral
- Others
The route of administration segment for the thrombocytopenia market is segmented into oral, parenteral and others.
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
On the basis of end-users, the thrombocytopenia market is segmented into hospitals, specialty clinics, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the thrombocytopenia market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.
Thrombocytopenia Market Regional Analysis/Insights
The Thrombocytopenia market is analysed and market size insights and trends are provided by country, type, drugs, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Thrombocytopenia market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the thrombocytopenia market because of the growing prevalence of thrombocytopenia in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to number of population and rising healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Thrombocytopenia Market Share Analysis
The Thrombocytopenia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to thrombocytopenia market.
Some of the major players operating in the thrombocytopenia market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Jerusalem)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (US)
- Merck & Co., Inc. (US)
- Allergan (Ireland)
- AstraZeneca (UK)
- AbbVie Inc. (US)
- Johnson & Johnson Private Limited (US)
- Cipla Inc. (US)
- Abbott (US)
- Merck KGaA (Germany)
- Amneal Pharmaceuticals LLC. (US)
- Amgen Inc. (US)
- Boehringer Ingelheim International GmbH. (Germany)
- Eisai Co., Ltd. (Japan)
SKU-